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Communal MRSA
Methicillin-resistant 
Staphylococcus aureus (MRSA) 
infections occur frequently in 
healthy individuals outside of 
typical nosocomial settings. 
Jappe et al. examined 
outpatients in a German 
dermatology clinic to assess 
this community-associated 
MRSA (CA-MRSA). Significant 
risk factors for CA-MRSA 
infection included visits to 
foreign countries or contact 
with foreigners. There was no 
evidence that patients with 
atopic dermatitis were prone to 
CA-MRSA infection. This study 
underscores the importance of 
clinical dermatologists to MRSA 
epidemiology and suggests that 
a resistance profile of all skin 
diseases with Panton–Valentine 
leukocidin–positive S. aureus 
and CA-MRSA be obtained, as 
this gene may be an informative 
epidemiological marker.  
See page 2655
Balancing Act
For psoriasis, therapies such 
as efalizumab, used to quiet 
the immune response to 
self-antigens, may impair the 
adaptive immune response. 
Krueger and colleagues 
demonstrated that efalizumab 
treatment successfully 
yielded a decreased yet 
substantial response to φX174 
immunization. The IgM-to-IgG 
isotype switch, which requires 
T-cell activation, was blocked 
in the treated immunized 
subjects, suggesting impaired 
T-cell response to the protein-
based antigen; however, 
subsequent exposure to the 
antigen following efalizumab 
discontinuation resulted in IgG 
production. See page 2615
Candida Clearance
Chronic mucocutaneous candidiasis (CMC) 
is thought to stem from an underlying defect 
in the adaptive immune system. T helper 17 
(Th17) cells, which produce IL-17, have 
been implicated in autoimmune diseases 
as well as in host defense against Candida 
albicans. Following stimulation with C. 
albicans, peripheral blood mononuclear 
cells (PBMCs) from CMC patients exhibit-
ed decreased secretion of Th17-associated 
cytokines compared with PBMCs from 
immunocompetent patients. The number of 
IL-17-producing cells was also decreased 
in CMC patients. These findings, together with a diminished stimulation of epithelial 
cells, offer insight into why CMC patients suffer from mucosal membrane and skin 
candidiasis and not systemic candidiasis. See page 2640
The ERK Prognosis
Currently, melanoma thickness and histopatho-
logic ulceration serve as prognostic markers for 
classification of malignant tumors. Previous stud-
ies have detected NRAS and BRAF mutations in a 
considerable percentage of primary melanomas; 
Jovanovic and colleagues further examined the 
effects of these mutations and activation of Akt and 
extracellular signal–regulated kinase (ERK) on sur-
vival in primary cutaneous melanomas. Whereas 
NRAS mutations were correlated with intense 
activation of the Raf-MEK-ERK and PI3K-Akt path-
ways, mutated BRAF exhibited a relatively low 
potential to activate ERK. Importantly, the absence 
of cytoplasmic activation of ERK was a significant adverse prognostic marker, as was 
ulceration in tumors containing BRAF mutations. See page 2696
No Antigens Required
Patients with Sézary syndrome, the most 
common type of cutaneous T-cell lympho-
ma, have a 5-year survival rate of only 11%. 
In contrast to nonspecific immunotherapy, 
dendritic cells (DCs)—the most potent 
antigen-presenting cells—can be primed to 
stimulate antitumor immune responses. Ni 
and colleagues primed monocyte-derived 
DCs with mRNA from Sézary cells and 
observed the induction of antitumor IFN-γ-producing cytotoxic T lymphocytes. Effector 
T cells expanded following DC stimulation, whereas regulatory T cells, which are a 
major immunological obstacle to antitumor vaccine development, failed to respond. 
One of the advantages of this approach is that it does not require tumor-specific anti-
gen profiles for successful clinical vaccination. See page 2631 
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